BGI Reports the Availability of RT-PCR SARS-CoV-2 Test for Clinical Use in the US
Shots:
- BGI’s Real-Time Fluorescent RT-PCR test is now commercially available in the US for detecting SARS-CoV-2. Following the FDA’s guidance- BGI’s detection kit is eligible to be used instantly to accelerate clinical testing for COVID-19
- BGI has applied to the US FDA for EUA for its detection kit and has received NMPA’s approval on Jan 26- 2020- followed by CE-IVD marking on Mar 2- 2020.
- BCI has scaled up manufacturing with a daily capacity of up to 300-000 reactions per day and is distributing its SARS-CoV-2 detection kits to 50+ countries and regions around the globe
Click here to read full press release/ article | Ref: BGI | Image: BGI
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com